Related Experiment Videos
Sulpiride in tardive dyskinesia
M Schwartz1, L Moguillansky, G Lanyi
1Department of Neurology, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel.
Journal of Neurology, Neurosurgery, and Psychiatry
|September 1, 1990
Summary
Sulpiride effectively reduced involuntary movements in tardive dyskinesia patients. This dopamine D2 receptor antagonist showed significant benefits with no major side effects, offering a promising treatment option.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Tardive dyskinesia (TD) involves abnormal involuntary movements.
- Conventional dopamine antagonists (phenothiazines, butyrophenones) can worsen Parkinsonian signs.
- Need for effective TD treatments with improved side effect profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of sulpiride in treating tardive dyskinesia.
- To assess the impact of sulpiride on involuntary movements and Parkinsonian signs.
Main Methods:
- A study involving 15 patients diagnosed with tardive dyskinesia.
- Treatment administered with sulpiride, a selective D2 receptor antagonist.
- Dosage did not exceed 600 mg daily; patients monitored for side effects.
Main Results:
- Sulpiride significantly reduced abnormal involuntary movements in most patients (p < 0.01).
- Marked improvement observed in 12 out of 15 patients.
- No significant side effects were reported during the trial or follow-up.
Conclusions:
- Sulpiride demonstrates significant efficacy in reducing tardive dyskinesia symptoms.
- Low doses of sulpiride are effective and well-tolerated.
- Sulpiride presents a favorable option for managing tardive dyskinesia.